Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of Renin–Angiotensin–Aldosterone Inhibitors on Early Outcomes of Hypertensive COVID-19 Patients: A Randomized Triple-Blind Clinical Trial
Farhad Najmeddin, Maedeh Solhjoo, Haleh Ashraf, et al.
American Journal of Hypertension (2021) Vol. 34, Iss. 11, pp. 1217-1226
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Atherosclerosis, Cardiovascular Disease, and COVID-19: A Narrative Review
Carles Vilaplana-Carnerero, Maria Giner‐Soriano, Ángela Domı́nguez, et al.
Biomedicines (2023) Vol. 11, Iss. 4, pp. 1206-1206
Open Access | Times Cited: 18
Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
Chenyang Zhang, Huaqing Jin, Yi Feng Wen, et al.
Frontiers in Public Health (2021) Vol. 9
Open Access | Times Cited: 38
Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial
Göran Tornling, Rohit Batta, Joanna C. Porter, et al.
EClinicalMedicine (2021) Vol. 41, pp. 101152-101152
Open Access | Times Cited: 35
Renin–Angiotensin–Aldosterone Inhibitors and COVID-19 Infection
Vasiliki Tsampasian, Natasha Corballis, Vassilios S. Vassiliou
Current Hypertension Reports (2022) Vol. 24, Iss. 10, pp. 425-433
Open Access | Times Cited: 20
Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research
Jordan Loader, Frances Taylor, Erik Lampa, et al.
Journal of the American Heart Association (2022) Vol. 11, Iss. 11
Open Access | Times Cited: 19
Effects of Renin–Angiotensin System Inhibitors on Mortality and Disease Severity of COVID-19 Patients: A Meta-analysis of Randomized Controlled Trials
Juntao Yin, Chaoyang Wang, Xiaoyong Song, et al.
American Journal of Hypertension (2022) Vol. 35, Iss. 5, pp. 462-469
Open Access | Times Cited: 18
Impact of renin–angiotensin–aldosterone system inhibitors on COVID-19
Yasushi Matsuzawa, Kazuo Kimura, Hisao Ogawa, et al.
Hypertension Research (2022) Vol. 45, Iss. 7, pp. 1147-1153
Open Access | Times Cited: 18
A Meta-Analysis of the Impact of Using Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin II Receptor Blockers (ARBs) on Mortality, Severity, and Healthcare Resource Utilization in Patients with COVID-19
Ruijuan Li, Jie Zhang, Liang Ren
Advances in respiratory medicine (2025) Vol. 93, Iss. 1, pp. 4-4
Open Access
SARS-CoV-2 Spike Protein Intensifies Cerebrovascular Complications in Diabetic hACE2 Mice through RAAS and TLR Signaling Activation
Faith N. Burnett, Maha Coucha, Deanna R. Bolduc, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 22, pp. 16394-16394
Open Access | Times Cited: 8
Angiotensin-Converting Enzyme (ACE) level, but not ACE gene polymorphism, is associated with prognosis of COVID-19 infection: Implications for diabetes and hypertension
Onur Elbasan, Feyza Bayram, Ceyda Dinçer Yazan, et al.
PLoS ONE (2023) Vol. 18, Iss. 7, pp. e0288338-e0288338
Open Access | Times Cited: 7
An Update of Carbazole Treatment Strategies for COVID-19 Infection
Maria Grazia Bonomo, Anna Caruso, Hussein El‐Kashef, et al.
Applied Sciences (2023) Vol. 13, Iss. 3, pp. 1522-1522
Open Access | Times Cited: 6
Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials
Matthew M.Y. Lee, Toru Kondo, Ross T. Campbell, et al.
European Heart Journal - Cardiovascular Pharmacotherapy (2023) Vol. 10, Iss. 1, pp. 68-80
Open Access | Times Cited: 6
Cardiovascular drugs and COVID‐19 clinical outcomes: a systematic review and meta‐analysis of randomized controlled trials
Innocent G. Asiimwe, Sudeep Pushpakom, Richard M. Turner, et al.
British Journal of Clinical Pharmacology (2022) Vol. 88, Iss. 8, pp. 3577-3599
Open Access | Times Cited: 10
Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in hospitalized patients with COVID-19: an updated systematic review and meta-analysis of randomized clinical trials
Joseph Alexander Paguio, Bruce Adrian Casipit, Tara A John, et al.
Expert Review of Cardiovascular Therapy (2023) Vol. 21, Iss. 3, pp. 219-226
Closed Access | Times Cited: 5
Severe COVID-19 and preexisting hypertension: a matter of age?
Osamu Yamazaki, Shigeru Shibata
Hypertension Research (2022) Vol. 45, Iss. 9, pp. 1523-1525
Open Access | Times Cited: 9
Renin–angiotensin system blockers during the COVID-19 pandemic: an update for patients with hypertension and chronic kidney disease
Marieta Theodorakopoulou, Maria Eleni Alexandrou, Afroditi Boutou, et al.
Clinical Kidney Journal (2021) Vol. 15, Iss. 3, pp. 397-406
Open Access | Times Cited: 11
Association of Cardiovascular Medications With Adverse Outcomes in a Matched Analysis of a National Cohort of Patients With COVID-19
Leonard Kuan‐Pei Wang, Yong‐Fang Kuo, Jordan Westra, et al.
American Journal of Medicine Open (2023) Vol. 9, pp. 100040-100040
Open Access | Times Cited: 4
Admission systolic blood pressure and obesity correlate with fatal and severe acute COVID-19 in the population of New Orleans, LA.
Dahlene N. Fusco, Sharon Liu, Marc Theberge, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Updates on Renin–Angiotensin System Blockers in Hypertensive Patients With COVID-19
Shigeru Shibata, Takuya Kishi
American Journal of Hypertension (2021) Vol. 34, Iss. 11, pp. 1145-1147
Open Access | Times Cited: 6
The effect of renin–angiotensin–aldosterone system inhibitors in patients with hypertension and COVID-19: A meta-analysis of randomized controlled trials and propensity score-matched studies
Kai Zhang, Lanxin Cao, Nanxia Xuan, et al.
Journal of Intensive Medicine (2022) Vol. 2, Iss. 4, pp. 282-290
Open Access | Times Cited: 4
The effects of antihypertensive medications on severity and outcomes of COVID19
Mehmet Ağırbaşlı
Journal of Human Hypertension (2022) Vol. 36, Iss. 10, pp. 875-879
Open Access | Times Cited: 4
Lack of Benefit of Renin-Angiotensin System Inhibitors in COVID-19
Matthew M.Y. Lee, John J.V. McMurray
JAMA (2023) Vol. 329, Iss. 14, pp. 1155-1155
Open Access | Times Cited: 2
Final results of BIRCOV trial (ARB, ACEI, DRi in COVID-19)
Д.Д. Іванов, Mariia Ivanova, Tommy Crestanello
KIDNEYS (2021) Vol. 10, Iss. 3, pp. 143-149
Open Access | Times Cited: 4
Blood Pressure Control Following Angiotensin‐Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers: Insights from a Triple‐Blind, Randomized, Clinical Trial
Amin Sharifan, Maryam Bahreini, Haleh Ashraf, et al.
The Journal of Clinical Pharmacology (2023) Vol. 63, Iss. 11, pp. 1205-1209
Closed Access | Times Cited: 1
The dynamics of hypertension and renal function in CKD and non-CKD patients affected with COVID-19 – final results of BIRCOV trial
Д.Д. Іванов, Antolii Gozhenko, Mariia Ivanova, et al.
European Journal of Clinical and Experimental Medicine (2023) Vol. 21, Iss. 2, pp. 230-238
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top